- Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
- Motley Fool
1 Soaring Growth Stock to Buy and Hold for 10 Years
Let's look beyond the biotech's performance this year.
- Zacks
Best Momentum Stocks to Buy for July 3rd
SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024.
